fda compounding glp-1 enforcement news New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA Enforcement - 503B GLP-1

If you dont prioritize changing your lifestyle habits while taking a GLP-1, when you go off the medication, the likelihood of regaining weight is high

Glutamate transporter GLT-1 as a therapeutic target for substance use disorders

Findings indicated that when added to standard care, semaglutide decreased the occurrence of a composite of cardiovascular-related deaths, non-fatal heart attacks, or non-fatal strokes over an average follow-up period of 39.8 9.4 months in this group compared to the placebo group

If you have any questions or concerns about using this formulation, or if you would like to discuss potential drug interactions in more detail, please reach out to us at Bayview Pharmacy

EMJ 5 , 94103 (2020)